Skip to main content
Top
Published in: Calcified Tissue International 3/2020

01-03-2020 | Original Research

Evaluation of a Panel of MicroRNAs that Predicts Fragility Fracture Risk: A Pilot Study

Authors: Aurélie Ladang, Charlotte Beaudart, Médéa Locquet, Jean-Yves Reginster, Olivier Bruyère, Etienne Cavalier

Published in: Calcified Tissue International | Issue 3/2020

Login to get access

Abstract

The assessment of fragility fracture risk based on bone densitometry and FRAX°, although commonly used, has shown some limitations. MicroRNAs (miRNAs) are promising biomarkers known to regulate post-transcriptional gene expression. Many studies have already shown that microRNAs are involved in bone homeostasis by modulating osteoblast and osteoclast gene expression. In this pilot study, we investigated the ability of an miRNA panel (namely, the OsteomiR° score) to predict fragility fracture risk in older people. miRNAs were extracted from the sera of 17 persons who developed a fracture within 3 years of collecting the serum and 16 persons who did not experience fractures in the same period. Nineteen miRNAs known to be involved in bone homeostasis were assessed, and 10 miRNAs were employed to calculate the OsteomiR° score. We found a trend towards higher OsteomiR° scores in individuals who experienced fractures compared to control subjects. The most suitable cut-off that maximized sensitivity and specificity was determined by ROC curve analysis, and a positive predictive value of 68% and a sensitivity of 76% were obtained. The OsteomiR° score was higher in osteopenic and osteoporotic subjects compared to subjects with a normal T score. Additionally, the OsteomiR° score predicted more fracture events than the recommended “need-to-treat” thresholds based on FRAX° 10-year probability. miRNAs reflect impairments in bone homeostasis several years before the occurrence of a fracture. The OsteomiR° score seems to be a promising miRNA panel for fragility fracture risk prediction and might have added value compared to FRAX°. Given the limited cohort size, further studies should be dedicated to validating the OsteomiR° score.
Literature
1.
go back to reference Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(2):4–9CrossRef Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(2):4–9CrossRef
2.
go back to reference Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475PubMedCrossRef Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475PubMedCrossRef
3.
go back to reference Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA (2000) Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 11(5):460–466PubMedCrossRef Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA (2000) Deterioration in quality of life following hip fracture: a prospective study. Osteoporos Int 11(5):460–466PubMedCrossRef
4.
go back to reference Melton LJ, Johnell O, Lau E, Mautalen CA, Seeman E (2004) Osteoporosis and the global competition for health care resources. J Bone Miner Res 19(7):1055–1058PubMedCrossRef Melton LJ, Johnell O, Lau E, Mautalen CA, Seeman E (2004) Osteoporosis and the global competition for health care resources. J Bone Miner Res 19(7):1055–1058PubMedCrossRef
5.
go back to reference Reid IR (2015) Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med 277(6):690–706PubMedCrossRef Reid IR (2015) Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med 277(6):690–706PubMedCrossRef
6.
go back to reference Camacho PM et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-executive summary. Endocr Pract 22(4):1–42PubMedCrossRef Camacho PM et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-executive summary. Endocr Pract 22(4):1–42PubMedCrossRef
7.
go back to reference Johnell O et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20(7):1185–1194PubMedCrossRef Johnell O et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20(7):1185–1194PubMedCrossRef
8.
go back to reference Siris ES et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. J Am Med Assoc 286(22):2815–2822CrossRef Siris ES et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. J Am Med Assoc 286(22):2815–2822CrossRef
9.
go back to reference Kanis JA et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046CrossRefPubMed Kanis JA et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033–1046CrossRefPubMed
11.
go back to reference Sambrook PN et al (2007) Influence of fall related factors and bone strength on fracture risk in the frail elderly. Osteoporos Int 18(5):603–610PubMedCrossRef Sambrook PN et al (2007) Influence of fall related factors and bone strength on fracture risk in the frail elderly. Osteoporos Int 18(5):603–610PubMedCrossRef
12.
go back to reference Giangregorio LM et al (2012) FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 27(2):301–308PubMedCrossRef Giangregorio LM et al (2012) FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 27(2):301–308PubMedCrossRef
13.
14.
go back to reference Walter E, Dellago H, Grillari J, Dimai HP, Hackl M (2018) Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population. Bone 108:44–54PubMedCrossRef Walter E, Dellago H, Grillari J, Dimai HP, Hackl M (2018) Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population. Bone 108:44–54PubMedCrossRef
15.
go back to reference Hackl M, Heilmeier U, Weilner S, Grillari J (2016) Circulating microRNAs as novel biomarkers for bone diseases—complex signatures for multifactorial diseases? Mol Cell Endocrinol 432:83–95PubMedCrossRef Hackl M, Heilmeier U, Weilner S, Grillari J (2016) Circulating microRNAs as novel biomarkers for bone diseases—complex signatures for multifactorial diseases? Mol Cell Endocrinol 432:83–95PubMedCrossRef
16.
go back to reference Foessl I, Kotzbeck P, Obermayer-Pietsch B (2019) miRNAs as novel biomarkers for bone related diseases. J Lab Precis Med 4(2–2):2–2CrossRef Foessl I, Kotzbeck P, Obermayer-Pietsch B (2019) miRNAs as novel biomarkers for bone related diseases. J Lab Precis Med 4(2–2):2–2CrossRef
17.
go back to reference Tie Y, Liu B, Fu H, Zheng X (2009) Circulating miRNA and cancer diagnosis. Sci China Ser C Life Sci 52(12):1117–1122CrossRef Tie Y, Liu B, Fu H, Zheng X (2009) Circulating miRNA and cancer diagnosis. Sci China Ser C Life Sci 52(12):1117–1122CrossRef
18.
go back to reference Meder B et al (2011) MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 106(1):13–23PubMedCrossRef Meder B et al (2011) MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 106(1):13–23PubMedCrossRef
19.
go back to reference McClelland AD, Kantharidis P (2013) microRNA in the development of diabetic complications. Clin Sci 126(2):95–110CrossRef McClelland AD, Kantharidis P (2013) microRNA in the development of diabetic complications. Clin Sci 126(2):95–110CrossRef
20.
go back to reference He P et al (2016) miR-141 modulates osteoblastic cell proliferation by regulating the target gene of IncRNA H19 and IncRNA H19-derived miR-675. Am J Transl Res 8(4):1780–1788PubMedPubMedCentral He P et al (2016) miR-141 modulates osteoblastic cell proliferation by regulating the target gene of IncRNA H19 and IncRNA H19-derived miR-675. Am J Transl Res 8(4):1780–1788PubMedPubMedCentral
23.
go back to reference Cao F, Zhan J, Chen X, Zhang K, Lai R, Feng Z (2017) miR-214 promotes periodontal ligament stem cell osteoblastic differentiation by modulating Wnt/β-catenin signaling. Mol Med Rep 16(6):9301–9308PubMedPubMedCentralCrossRef Cao F, Zhan J, Chen X, Zhang K, Lai R, Feng Z (2017) miR-214 promotes periodontal ligament stem cell osteoblastic differentiation by modulating Wnt/β-catenin signaling. Mol Med Rep 16(6):9301–9308PubMedPubMedCentralCrossRef
25.
26.
go back to reference Peng H, Lu SL, Bai Y, Fang X, Huang H, Zhuang XQ (2018) MiR-133a inhibits fracture healing via targeting RUNX2/BMP2. Eur Rev Med Pharmacol Sci 22(9):2519–2526PubMed Peng H, Lu SL, Bai Y, Fang X, Huang H, Zhuang XQ (2018) MiR-133a inhibits fracture healing via targeting RUNX2/BMP2. Eur Rev Med Pharmacol Sci 22(9):2519–2526PubMed
27.
go back to reference Deng Y et al (2013) Effects of a miR-31, Runx2, and Satb2 regulatory loop on the osteogenic differentiation of bone mesenchymal stem cells. Stem Cells Dev 22(16):2278–2286PubMedCrossRef Deng Y et al (2013) Effects of a miR-31, Runx2, and Satb2 regulatory loop on the osteogenic differentiation of bone mesenchymal stem cells. Stem Cells Dev 22(16):2278–2286PubMedCrossRef
28.
go back to reference Zhang L et al (2017) Overexpression of MiR-335-5p promotes bone formation and regeneration in mice. J Bone Miner Res 32(12):2466–2475PubMedCrossRef Zhang L et al (2017) Overexpression of MiR-335-5p promotes bone formation and regeneration in mice. J Bone Miner Res 32(12):2466–2475PubMedCrossRef
29.
go back to reference Huang J, Song G, Yin Z, Fu Z, Ye Z (2017) MiR-29a and messenger RNA expression of bone turnover markers in canonical Wnt pathway in patients with ankylosing spondylitis. Clin Lab 63(5–6):955–960PubMed Huang J, Song G, Yin Z, Fu Z, Ye Z (2017) MiR-29a and messenger RNA expression of bone turnover markers in canonical Wnt pathway in patients with ankylosing spondylitis. Clin Lab 63(5–6):955–960PubMed
30.
go back to reference Mäkitie RE, Hackl M, Niinimäki R, Kakko S, Grillari J, Mäkitie O (2018) Altered MicroRNA profile in osteoporosis caused by impaired WNT signaling. J. Clin. Endocrinol. Metab. 103(5):1985–1996PubMedCrossRef Mäkitie RE, Hackl M, Niinimäki R, Kakko S, Grillari J, Mäkitie O (2018) Altered MicroRNA profile in osteoporosis caused by impaired WNT signaling. J. Clin. Endocrinol. Metab. 103(5):1985–1996PubMedCrossRef
32.
go back to reference Seeliger C et al (2014) Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures. J Bone Miner Res 29(8):1718–1728PubMedCrossRef Seeliger C et al (2014) Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures. J Bone Miner Res 29(8):1718–1728PubMedCrossRef
33.
go back to reference Kocijan R et al (2016) Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures. J Clin Endocrinol Metab 101(11):4125–4134PubMedCrossRef Kocijan R et al (2016) Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures. J Clin Endocrinol Metab 101(11):4125–4134PubMedCrossRef
34.
go back to reference Feichtinger X et al (2018) Bone-related circulating MicroRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their Association to Bone Microstructure and Histomorphometry. Sci Rep 8(1):4867PubMedPubMedCentralCrossRef Feichtinger X et al (2018) Bone-related circulating MicroRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their Association to Bone Microstructure and Histomorphometry. Sci Rep 8(1):4867PubMedPubMedCentralCrossRef
35.
go back to reference Heilmeier U et al (2016) Serum miRNA signatures are indicative of skeletal fractures in postmenopausal women with and without type 2 diabetes and influence osteogenic and adipogenic differentiation of adipose tissue-derived mesenchymal stem cells in vitro. J Bone Miner Res 31(12):2173–2192PubMedCrossRef Heilmeier U et al (2016) Serum miRNA signatures are indicative of skeletal fractures in postmenopausal women with and without type 2 diabetes and influence osteogenic and adipogenic differentiation of adipose tissue-derived mesenchymal stem cells in vitro. J Bone Miner Res 31(12):2173–2192PubMedCrossRef
36.
go back to reference Beaudart C et al (2015) Quality of life and physical components linked to sarcopenia: the SarcoPhAge study. Exp Gerontol 69:103–110PubMedCrossRef Beaudart C et al (2015) Quality of life and physical components linked to sarcopenia: the SarcoPhAge study. Exp Gerontol 69:103–110PubMedCrossRef
37.
go back to reference Norlund L et al (1997) Reference intervals for the glomerular filtration rate and cell-proliferation markers: serum cystatin C and serum β2-microglobulin/cystatin C-ratio. Scand J Clin Lab Investig 57(6):463–470CrossRef Norlund L et al (1997) Reference intervals for the glomerular filtration rate and cell-proliferation markers: serum cystatin C and serum β2-microglobulin/cystatin C-ratio. Scand J Clin Lab Investig 57(6):463–470CrossRef
38.
go back to reference Johansson H et al (2011) A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int 22(2):453–461PubMedCrossRef Johansson H et al (2011) A FRAX® model for the assessment of fracture probability in Belgium. Osteoporos Int 22(2):453–461PubMedCrossRef
39.
go back to reference Briot K et al (2012) Actualisation 2012 des recommandations françaises du traitement médicamenteux de l’ostéoporose post-ménopausique. Revue du rhumatisme. 79(3):264–274CrossRef Briot K et al (2012) Actualisation 2012 des recommandations françaises du traitement médicamenteux de l’ostéoporose post-ménopausique. Revue du rhumatisme. 79(3):264–274CrossRef
40.
go back to reference Chen Y, Alman BA (2009) Wnt pathway, an essential role in bone regeneration. J Cell Biochem 106(3):353–362PubMedCrossRef Chen Y, Alman BA (2009) Wnt pathway, an essential role in bone regeneration. J Cell Biochem 106(3):353–362PubMedCrossRef
41.
go back to reference Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23(2):423–431PubMedCrossRef Kanis JA, Oden A, Johansson H, McCloskey E (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23(2):423–431PubMedCrossRef
42.
go back to reference Aubry-Rozier B, Stoll D, Krieg MA, Lamy O, Hans D (2013) What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture? Clin Rheumatol 32(2):219–223PubMedCrossRef Aubry-Rozier B, Stoll D, Krieg MA, Lamy O, Hans D (2013) What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture? Clin Rheumatol 32(2):219–223PubMedCrossRef
43.
go back to reference Chen XF, Li XL, Zhang H, Liu GJ (2014) Were you identified to be at high fracture risk by FRAX® before your osteoporotic fracture occurred? Clin Rheumatol 33(5):693–698PubMedCrossRef Chen XF, Li XL, Zhang H, Liu GJ (2014) Were you identified to be at high fracture risk by FRAX® before your osteoporotic fracture occurred? Clin Rheumatol 33(5):693–698PubMedCrossRef
45.
go back to reference Poynard T et al (2011) Applicability and precautions of use of liver injury biomarker FibroTest A reappraisal at 7 years of age. BMC Gastroenterol 11(39):39PubMedPubMedCentralCrossRef Poynard T et al (2011) Applicability and precautions of use of liver injury biomarker FibroTest A reappraisal at 7 years of age. BMC Gastroenterol 11(39):39PubMedPubMedCentralCrossRef
Metadata
Title
Evaluation of a Panel of MicroRNAs that Predicts Fragility Fracture Risk: A Pilot Study
Authors
Aurélie Ladang
Charlotte Beaudart
Médéa Locquet
Jean-Yves Reginster
Olivier Bruyère
Etienne Cavalier
Publication date
01-03-2020
Publisher
Springer US
Published in
Calcified Tissue International / Issue 3/2020
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-019-00628-8

Other articles of this Issue 3/2020

Calcified Tissue International 3/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.